JP2006500346A - 癌の処置のためのｖｅｇｆ受容体チロシンキナーゼ阻害剤の組み合わせ - Google Patents

癌の処置のためのｖｅｇｆ受容体チロシンキナーゼ阻害剤の組み合わせ Download PDF

Info

Publication number
JP2006500346A
JP2006500346A JP2004527018A JP2004527018A JP2006500346A JP 2006500346 A JP2006500346 A JP 2006500346A JP 2004527018 A JP2004527018 A JP 2004527018A JP 2004527018 A JP2004527018 A JP 2004527018A JP 2006500346 A JP2006500346 A JP 2006500346A
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
effective amount
warm
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004527018A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006500346A5 (https=
Inventor
ウェッジ，スティーブン・ロバート
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of JP2006500346A publication Critical patent/JP2006500346A/ja
Publication of JP2006500346A5 publication Critical patent/JP2006500346A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2004527018A 2002-08-09 2003-08-05 癌の処置のためのｖｅｇｆ受容体チロシンキナーゼ阻害剤の組み合わせ Pending JP2006500346A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0218526.2A GB0218526D0 (en) 2002-08-09 2002-08-09 Combination therapy
PCT/GB2003/003390 WO2004014426A1 (en) 2002-08-09 2003-08-05 Combination of vegf receptor tyrosine kinase inhibitors for treatment of cancer

Publications (2)

Publication Number Publication Date
JP2006500346A true JP2006500346A (ja) 2006-01-05
JP2006500346A5 JP2006500346A5 (https=) 2006-08-31

Family

ID=9942013

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004527018A Pending JP2006500346A (ja) 2002-08-09 2003-08-05 癌の処置のためのｖｅｇｆ受容体チロシンキナーゼ阻害剤の組み合わせ

Country Status (14)

Country Link
US (2) US20050245549A1 (https=)
EP (1) EP1534338A1 (https=)
JP (1) JP2006500346A (https=)
KR (1) KR20050059060A (https=)
CN (1) CN100556456C (https=)
BR (1) BR0313117A (https=)
CA (1) CA2495489A1 (https=)
GB (1) GB0218526D0 (https=)
IL (1) IL166625A0 (https=)
MX (1) MXPA05001457A (https=)
NO (1) NO20050528L (https=)
NZ (1) NZ537754A (https=)
WO (1) WO2004014426A1 (https=)
ZA (1) ZA200501061B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010504949A (ja) * 2006-09-29 2010-02-18 アストラゼネカ アクチボラグ Ｚｄ６４７４とベバシズマブの癌療法のための組合せ

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ301689B6 (cs) 1999-11-05 2010-05-26 Astrazeneca Ab Derivát chinazolinu a farmaceutický prostredek, který ho obsahuje
GB0008269D0 (en) 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
ES2267748T3 (es) 2000-04-07 2007-03-16 Astrazeneca Ab Compuestos de quinazolina.
GB0126879D0 (en) * 2001-11-08 2002-01-02 Astrazeneca Ab Combination therapy
JP4608215B2 (ja) 2002-02-01 2011-01-12 アストラゼネカ アクチボラグ キナゾリン化合物
GB0218526D0 (en) * 2002-08-09 2002-09-18 Astrazeneca Ab Combination therapy
GB0223380D0 (en) * 2002-10-09 2002-11-13 Astrazeneca Ab Combination therapy
RU2350618C2 (ru) 2002-11-04 2009-03-27 Астразенека Аб ПРОИЗВОДНЫЕ ХИНАЗОЛИНА В КАЧЕСТВЕ ИНГИБИТОРОВ Src ТИРОЗИНКИНАЗЫ
PT1592423E (pt) * 2003-02-13 2011-06-16 Astrazeneca Ab Terapia de combinação de zd6474 com 5-fu e/ou cpt-11
GB0310401D0 (en) * 2003-05-07 2003-06-11 Astrazeneca Ab Therapeutic agent
EP1648465B1 (en) * 2003-07-10 2010-08-25 AstraZeneca AB Use of the quinazoline derivative zd6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability
KR20070072543A (ko) * 2004-09-27 2007-07-04 아스트라제네카 아베 Ｚｄ6474 및 이마티닙을 포함하는 병합법
GB0424339D0 (en) * 2004-11-03 2004-12-08 Astrazeneca Ab Combination therapy
RU2007134908A (ru) * 2005-04-14 2009-05-20 Вайет (Us) Применение ингибитора активности киназы рецептора эпидермального фактора роста для лечения пациентов, невосприимчивых к гефитинибу
US20080219977A1 (en) * 2005-07-27 2008-09-11 Isaiah Josh Fidler Combinations Comprising Gemcitabine and Tyrosine Kinase Inhibitors for the Treatment of Pancreatic Cancer
GB0519879D0 (en) 2005-09-30 2005-11-09 Astrazeneca Ab Chemical process
CA2833706C (en) 2005-11-11 2014-10-21 Boehringer Ingelheim International Gmbh Quinazoline derivatives for the treatment of cancer diseases
WO2007071958A2 (en) * 2005-12-22 2007-06-28 Astrazeneca Ab Combination of zd6474 and pemetrexed
US20070258976A1 (en) * 2006-05-04 2007-11-08 Ward Keith W Combination Therapy for Diseases Involving Angiogenesis
AU2007299080B2 (en) * 2006-09-18 2013-04-18 Boehringer Ingelheim International Gmbh Method for treating cancer harboring EGFR mutations
PL2451445T3 (pl) 2009-07-06 2019-09-30 Boehringer Ingelheim International Gmbh Sposób suszenia BIBW2992, jego soli i stałych preparatów farmaceutycznych zawierających tę substancję czynną
US9242965B2 (en) 2013-12-31 2016-01-26 Boehringer Ingelheim International Gmbh Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
GB201516905D0 (en) * 2015-09-24 2015-11-11 Stratified Medical Ltd Treatment of Neurodegenerative diseases

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002041882A2 (en) * 2000-11-22 2002-05-30 Novartis Ag Combination comprising an agent decreasing vegf activity and an agent decreasing egf activity

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0008269D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
GB0126879D0 (en) * 2001-11-08 2002-01-02 Astrazeneca Ab Combination therapy
DE60311788T2 (de) * 2002-04-16 2007-11-22 Astrazeneca Ab Kombinationstherapie zur behandlung von krebs
KR20050056190A (ko) * 2002-08-09 2005-06-14 아스트라제네카 아베 암의 치료에서의 방사선 요법과 함께 혈관 내피 성장 인자수용체의 억제제인 ｚｄ6474의 병행 치료
GB0218526D0 (en) * 2002-08-09 2002-09-18 Astrazeneca Ab Combination therapy
GB0223380D0 (en) * 2002-10-09 2002-11-13 Astrazeneca Ab Combination therapy
GB0223854D0 (en) * 2002-10-12 2002-11-20 Astrazeneca Ab Therapeutic treatment
PT1592423E (pt) * 2003-02-13 2011-06-16 Astrazeneca Ab Terapia de combinação de zd6474 com 5-fu e/ou cpt-11
GB0316127D0 (en) * 2003-07-10 2003-08-13 Astrazeneca Ab Combination therapy
EP1648465B1 (en) * 2003-07-10 2010-08-25 AstraZeneca AB Use of the quinazoline derivative zd6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability
GB0412074D0 (en) * 2004-05-29 2004-06-30 Astrazeneca Ab Combination product
KR20070072543A (ko) * 2004-09-27 2007-07-04 아스트라제네카 아베 Ｚｄ6474 및 이마티닙을 포함하는 병합법
GB0424339D0 (en) * 2004-11-03 2004-12-08 Astrazeneca Ab Combination therapy
WO2007071958A2 (en) * 2005-12-22 2007-06-28 Astrazeneca Ab Combination of zd6474 and pemetrexed

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002041882A2 (en) * 2000-11-22 2002-05-30 Novartis Ag Combination comprising an agent decreasing vegf activity and an agent decreasing egf activity

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010504949A (ja) * 2006-09-29 2010-02-18 アストラゼネカ アクチボラグ Ｚｄ６４７４とベバシズマブの癌療法のための組合せ

Also Published As

Publication number Publication date
US20050245549A1 (en) 2005-11-03
ZA200501061B (en) 2007-01-31
AU2003252976A1 (en) 2004-02-25
CN100556456C (zh) 2009-11-04
IL166625A0 (en) 2006-01-15
WO2004014426A1 (en) 2004-02-19
CA2495489A1 (en) 2004-02-19
US20100130493A1 (en) 2010-05-27
NZ537754A (en) 2008-02-29
NO20050528L (no) 2005-05-03
MXPA05001457A (es) 2005-06-06
EP1534338A1 (en) 2005-06-01
CN1674938A (zh) 2005-09-28
GB0218526D0 (en) 2002-09-18
BR0313117A (pt) 2005-07-05
KR20050059060A (ko) 2005-06-17

Similar Documents

Publication Publication Date Title
US20100130493A1 (en) Combination of vegf receptor tyrosine kinase inhibitors for treatment of cancer
JP2007526886A (ja) 血管新生および／または血管透過性増大に関連する疾患の処置における、プラチナ系抗腫瘍剤および任意の電離放射線と組み合わせてのキナゾリン誘導体ｚｄ６４７４の使用
US20100179142A1 (en) Cancer Combination Therapy Comprising AZD2171 and ZD1839
KR20070072543A (ko) Ｚｄ6474 및 이마티닙을 포함하는 병합법
EP1496909B1 (en) Combination therapy for the treatment of cancer
KR20070008651A (ko) 조합 요법
US20090176731A1 (en) Combination therapy of cancer with azd2171 and gemcitabine
AU2003252976B2 (en) Combination of VEGF receptor tyrosine kinase inhibitors for treatment of cancer
HK1089667B (en) Cancer combination therapy comprising azd2171 and zd1839
HK1071310B (en) Combination therapy for the treatment of cancer
HK1096022B (en) Combination therapy with azd-2171

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060713

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060713

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100311

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100610

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100617

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100913